SMO and colorectal cancer: This may possibly explain the disappointing clinical trial results of Smo inhibitors for treatment of colorectal cancer [15], as Smo inhibitors can merely abolish the canonical and Smo-dependent Hh activity, while leaving the PGE2-provoked and Smo-independent Hh activity in colorectal cancer cells unaffected.